Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...

IRFMN
Bianchi R., Gilardini A., Rodriguez-Menendez V., Oggioni V., Canta A., Colombo T., De
Michele G., Martone S., Sfacteria A., Piedemonte G., Grasso G., Beccaglia P., Ghezzi P.,
D’Incalci M., Lauria G., Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection
by erythropoietin without affecting tumour growth. Eur J Cancer 2007; 43: 710-717.
Salvati E., Leonetti C., Rizzo A., Scarsella M., Mottolese M., Galati R., Sperduti I., Stevens
M.F.G., D’Incalci M., Blasco M., Chiorino G., Bauwens S., Horard B., Gilson E., Stopacciaro
A., Zupi G., Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an
antitumor effect. J Clin Invest 2007; 117: 3236-3247.
Tavecchio M., Natoli C., Ubezio P., Erba E., D'Incalci M. Dynamics of cell cycle phase
perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NERproficient
cells, unravelled by a novel mathematical simulation approach. Cell Prolif 2007; 40:
885-904.
Lupi M., Matera G., Natoli C., Colombo V., Ubezio P. The contribution of p53 in the dynamics
of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle 2007; 6:
943-950.
Sessa C., Cresta S., Cerny T., Baselga J., Rota Caremoli E., Malossi A., Hess D., Trigo J.,
Zucchetti M., D'Incalci M., Zaniboni A., Capri G., Gatti B., Carminati P., Zanna C., Marsoni S.,
Gianni L. Concerted escalation of dose and dosing duration in a phase I study of the oral
camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol 2007; 18:
561-568.
D'Incalci M., Steward W.P., Gescher A.J. Modulation of response to cancer chemotherapeutic
agents by diet constituents. Is the available evidence sufficiently robust for rational advice for
patients? Cancer Treat Rev 2007; 33: 223-229.
Bagnati R., Bianchi G., Marangon E., Zuccato E., Fanelli R., Davoli E. Direct analysis of
isopropylthioxanthone (ITX) in milk by high-performance liquid chromatography/tandem mass
spectrometry. Rapid Commun Mass Spectrom 2007; 21: 1998-2002.
Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C.,
Marmiroli P., Bossi M., Oggioni N., D'Incalci M., De Coster R. Bortezomib-induced peripheral
neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol 2007; 204:
317-325.
Gordon M.O., Torri V., Miglior S., Floriani I., Miller J.P., Gao F., Adamsons F., Poli D.,
D'Agostino R.B., Kass M.A. Validated prediction model for the development for the
development of primary open-angle glaucoma in individuals with ocular hypertension.
Ophthalmology 2007; 114: 10-19.
Basse B., Ubezio P. A generalised age- and phase-structured model of human tumour cell
populations both unperturbed and exposed to a range of cancer terapies. Bull Math Biol 2007;
69: 1673-1690.
Vikhanskaya F., Lee M.K., Mazzoletti M., Broggini M., Sabapathy K. Cancer-derived p53
mutants suppress p53-target gene expression-potential mechanism for gain of function of
mutant p53. Nucleic Acids Res 2007; 35: 2093-2104.
28
RAPPORTO ATTIVITA’ 2007